Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
RARE
Ultragenyx Pharmaceu
$34.03
Chart
$35.4 (-3.87%)
$38.62 (-11.89%)
$44.85 (-24.12%)
$39.05 (-12.86%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
RARE
Ultragenyx Pharmaceu
Current Price
$34.03
Login to view Ultragenyx Pharmaceu (RARE) recommendation from the last 90 days from financial news and social media.
Chart
$35.4 (-3.87%)
$38.62 (-11.89%)
$44.85 (-24.12%)
$39.05 (-12.86%)
RARE Latest Headlines
Analyst ish On Ultragenyx Poised For Growth With Six Drug Approvals Expected By 2028. On Wednesday William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:) a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-.Since 2017 the company has commercialized four products which generated $560 million in revenue in 2024 up 29% year-over-year. In the first quarter of 2025 sales increased .Ultragenyx expects fiscal 2025 sales of $640 millio
Wed May 28, 2025
Analyst ish On Ultragenyx Poised For Growth With Six Drug Approvals Expected By 2028. On Wednesday William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:) a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-.Since 2017 the company has commercialized four products which generated $560 million in revenue in 2024 up 29% year-over-year. In the first quarter of 2025 sales increased .Ultragenyx expects fiscal 2025 sales of $640 millio
Wed May 28, 2025
Analyst ish On Ultragenyx Poised For Growth With Six Drug Approvals Expected By 2028. On Wednesday William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:) a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-.Since 2017 the company has commercialized four products which generated $560 million in revenue in 2024 up 29% year-over-year. In the first quarter of 2025 sales increased .Ultragenyx expects fiscal 2025 sales of $640 millio
Wed May 28, 2025
Analyst ish On Ultragenyx Poised For Growth With Six Drug Approvals Expected By 2028. On Wednesday William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:) a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-.Since 2017 the company has commercialized four products which generated $560 million in revenue in 2024 up 29% year-over-year. In the first quarter of 2025 sales increased .Ultragenyx expects fiscal 2025 sales of $640 millio
Wed May 28, 2025
Analyst ish On Ultragenyx Poised For Growth With Six Drug Approvals Expected By 2028. On Wednesday William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:) a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-.Since 2017 the company has commercialized four products which generated $560 million in revenue in 2024 up 29% year-over-year. In the first quarter of 2025 sales increased .Ultragenyx expects fiscal 2025 sales of $640 millio
Wed May 28, 2025
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. May 20 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases today reported the grant of 44805 restricted stock units of the companys common stock to 20 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the
Tue May 20, 2025
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights. Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)Cash of $62.5 million as of March 31 2025 expected to fund operations into 2027LONDON May 13 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:) (Mereo or the Company) a clinical-stage biopharmaceutical company focused on rare diseases today announced its financial results for the first quarter ended March
Tue May 13, 2025
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights. Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)Cash of $62.5 million as of March 31 2025 expected to fund operations into 2027LONDON May 13 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:) (Mereo or the Company) a clinical-stage biopharmaceutical company focused on rare diseases today announced its financial results for the first quarter ended March
Tue May 13, 2025
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights. Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)Cash of $62.5 million as of March 31 2025 expected to fund operations into 2027LONDON May 13 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:) (Mereo or the Company) a clinical-stage biopharmaceutical company focused on rare diseases today announced its financial results for the first quarter ended March
Tue May 13, 2025
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights. Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)Cash of $62.5 million as of March 31 2025 expected to fund operations into 2027LONDON May 13 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:) (Mereo or the Company) a clinical-stage biopharmaceutical company focused on rare diseases today announced its financial results for the first quarter ended March
Tue May 13, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
RARE Stock trends
RARE Stock performance
RARE Stock analysis
RARE investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
